Narrow-spectrum antibiotics are as effective as broad-spectrum antibiotics in the treatment of community-acquired pneumonia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Recent updates regarding the management and treatment of pneumonia in pediatric patients: a comprehensive review.Infection · 2025
   Review
2. Short lipopeptides specifically inhibit the growth of Propionibacterium acnes with a dual antibacterial and anti-inflammatory action.British journal of pharmacology · 2019
   Article
3. Short lipopeptides specifically inhibit the growth of Propionibacterium acnes with dual antibacterial and anti-inflammatory action.British journal of pharmacology · 2019
   Article
4. Recent Developments in Pediatric Community-Acquired Pneumonia.Current infectious disease reports · 2016
   Article

Corrections and comments

• Comment on
  Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia.2013

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as